Express Pharma

DECEMBER 2, 2024

By 2030, half of all US adults are predicted to be obese (New England Journal of Medicine). The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. This alarming trend presents a lucrative opportunity for drugmakers. However, the emergence of oral therapies is reshaping the landscape.

Labelling 126

Labelling Diabetes Drug Development 126

Pharma Marketing Network

MARCH 25, 2022

By 2030, it is estimated there will be only 4 potential family caregivers per older adult and some are also caring for children of their own. The FDA has studied the importance of caregivers to drug development and regulatory decision-making. 2 In 2019, there were 7 potential family caregivers per older adult.

Labelling 98

Labelling Drug Development 98

PharmaTech

JUNE 26, 2025

million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L. million (approximately US$1.99 million (approximately US$1.99 million (US$12.9

Dosage 59

Dosage Drug Development Vaccines Labelling 59

PharmaShots

APRIL 3, 2023

of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. vs 10%) The companies will discuss the findings with regulatory authorities, initiate a P-III study in adjuvant melanoma in 2023 & expand to additional tumor types, incl. 3 ADCs: Adcetris, Padcev & Tivdak.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40